SPECIAL ARTICLE
Malignant hyperthermia – what do we know in 2019?
1
1st Department of Anaesthesiology and Intensive Care, Medical University of Warsaw, Poland
2
Department of Anaesthesiology and Intensive Care, University of Warmia and Mazury in Olsztyn, Poland
3
Department of Neurology, Warsaw Medical University, Poland
4
Department of Anaesthesiology and Intensive Care, Medical University of Gdańsk, Poland
Publication date: 2019-08-30
Anaesthesiol Intensive Ther 2019;51(3):169-177
REFERENCES (32)
1.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Malignant hyperthermia: a review. Orphanet J Rare Dis 2015; 10: 93. doi: 10.1186/s13023-015-0310-1.
2.
Larach MG, Gronert GA, Allen GC, Brandon BW, Lehman EB. Clinical presentation, treatment andcomplications of malignant hyperthermia in North American from 1987 to 2006. Anesth Analog 2010; 110: 498-507. doi: 10.1213/ANE.0b013e3181c6b9b2.
3.
Riazi S, Larach MG, Hu C, Wijeysundera D, Massey C, Kraeva N. Malignant hyperthermia in Canada: characteristics ofindex anesthetics in 129 malignant hyperthermia susceptibleprobands. Anesth Analg 2014; 118: 381-387. doi: 10.2147/TCRM.S47632.
4.
Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB. Cardiac Arrests and Deaths Associated with Malignant Hyperthermia in North America from 1987 to 2006: A Report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States. Anesthesiology 2008; 108: 603-611. doi: 10.1097/ALN.0b013e318167aee2.
5.
Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin (2018) S1-Leitlinie: Therapie dermalignen Hyperthermie. Anästh Intensivmed 2018; 59: 204-208.
6.
Riazi S, Kraeva N, Hopkins PM. Malignant hyperthermia in the post-genomics era: new perspectives on an old concept. Anesthesiology 2018; 128: 168-180. doi: 10.1097/ALN.0000000000001878.
7.
Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J 1970; 17: 293-315.
8.
Sumitani M, Uchida K, Yasunaga H, et al. Prevalence of malignant hyperthermia and relationship with anesthetics in Japan: data from the diagnosis procedure combination database. Anesthesiology 2011; 114: 84-90. doi: 10.1097/ALN.0b013e318200197d.
9.
Mayzner-Zawadzka E. Current status of malignant hyperthermia in Poland. 23th Annual Meeting of the European Malignant Hyperthermia Group in Leipzig 2004.
10.
Sambuughin N, Holley H, Muldoon S, et al. Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population. Anesthesiology 2005; 102: 515-521. doi: 10.1097/ 00000542-200503000-00007.
11.
Stewart SL, Hogan K, Rosenberg H, Fletcher JE. Identification of the Arg1086His mutation in the alpha subunit of the voltage-dependent calcium channel (CACNA1S) in a North American family with malignant hyperthermia. Clin Genet 2001; 59: 178-184. doi: 10.1034/j.1399-0004.2001.590306.x.
12.
Stamm DS, Aylsworth AS, Stajich JM, et al. Native American myopathy: Congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia. Am J Med Genet Part A 2008; 146A: 1832-1841. doi: 10.1002/ajmg.a.32370.
13.
Schneiderbanger D, Johannsen S, Roewer N, et al. Management of malignant hyperthermia: diagnosis and treatment. Ther Clin Risk Manag 2014; 10: 355-362. doi: 10.2147/TCRM.S47632.
14.
Glahn KP, Ellis FR, Halsall PJ, et al. Recognizing and managing a malignant hyperthermia crisis: guidelines fromt he European Malignant Hyperthermia Group. Br J Anaesth 2010; 105: 417-420. doi: 10.1093/bja/aeq243.
15.
Voermans NC, Snoeck M, Jungbluth H. RYR1-related rhabdomyolysis: A common but probably underdiagnosed manifestation ofdefective skeletal muscle ryanodine receptor dysfunction. Rev Neurol 2016; 172: 546-558. doi: http://dx.doi.org/10.1016/j.ne....
16.
Litman RS, Flood CD, Kaplan RF, Kim YL, Tobin JR. Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry. Anesthesiology 2008; 109: 825-829. doi: 10.1097/ALN.0b013e31818958e5.
17.
Visoiu M, Young MC, Wieland K, Brandom BW. Anesthetic drugs and onset of malignant hyperthermia. Anesth Analg 2014; 118: 388-396. doi: 10.1213/ANE.0000000000000062.
18.
Burkman JM, Posner KL, Domino KB. Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions. Anesthesiology 2007; 106: 901-906. doi: 10.1097/01.anes. 0000265148.86566.68.
19.
Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-779. doi: 10.1097/00000542-199404000-00008.
20.
Krause T, GerbershagenMU, Fiege M, Weisshorn R, Wappler F. Dantrolene – a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59: 364-373. doi: 10.1111/j.1365-2044. 2004.03658.x.
23.
Hopkins PM, Rüffert H, Snoeck MM, et al.; European Malignant Hyperthermia Group. European Malignant Hyperthermia Group guidelines for investigation of malignant hyperthermia susceptibility. Br J Anaesth 2015; 115: 531-539. doi: 10.1093/bja/aev225.
24.
Litman RS, Griggs SM, Dowling JJ, Riazi S. Malignant hyperthermia susceptibility and related diseases. Anesthesiology 2018; 128: 159-167. doi: 10.1097/ALN.0000000000001877.
25.
Paasuke RT, Brownell AKW. Serum creatine kinase level as a screening test for susceptibility to malignant hyperthermia. JAMA 1986; 255: 769-771. doi: 10.1001/jama.1986.03370060083024.
26.
Kim TW, Nemergut ME. Preparation of modern anesthesia workstations for malignant hyperthermia susceptible patients: A review of past and present practice. Anesthesiology 2011; 114: 205-212.
27.
Sessler DI. Temperature monitoring and perioperative thermoregulation. Anesthesiology 2008; 109: 318-338.
28.
Larach MG, Brandom BW, Allen GC, et al. Malignant hyperthermia deaths related toinadequate temperature monitoring, 2007-2012: a report from the North Americanmalignant hyperthermia registry of the malignant hyperthermia association of theUnited States. Anesth Analg 2014; 119: 1359-1366.
29.
Barnes C, Stowell KM, Bulger T, Langton E, Pollock N. Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update. Anaesth Intensive Care 2015; 43: 98-104.
30.
In J, Ahn EJ, Lee DK, Kang H. Incidence of malignant hyperthermia in patients undergoing general anesthesia: Protocol for a systematic review and meta-analysis. Medicine 2017; 96: e9115. doi: 10.1097/MD.0000000000009115.
32.
Mellin-Olsen J, Staender S, Whitaker DK, Smith AF. The Helsinki Declaration on Patient Safety in Anaesthesiology. Eur J Anaesthesiol 2010; 27: 592-597. doi: 10.1097/EJA.0b013e32833b1adf.
| eISSN: | 1731-2531 |
| ISSN: | 1642-5758 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
